Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 274-281, October 2010

Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets

  • Anthony J. Chalmers, MD, PhD, FRCR

      Affiliations

    • Genome Damage and Stability Centre, University of Sussex, Brighton, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Anthony J. Chalmers, MD, PhD, FRCR, Brighton and Sussex Medical School and Genome Damage and Stability Centre, University of Sussex, Falmer BN1 9RQ, UK
    • ,
  • Mina Lakshman, PhD

      Affiliations

    • Departments of Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Norman Chan, BSc

      Affiliations

    • Departments of Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Robert G. Bristow, MD, PhD, FRCPC

      Affiliations

    • Departments of Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by operating grants from the Medical Research Council to AJC and the Terry Fox Research Institute, the Ontario Institute for Cancer Research, and an infrastructure grant from the Canadian Foundation for Innovation grant to the STTARR Innovation Facility to RGB. ML is a CIHR-EIRR21t Post-Doctoral Fellow, and RGB is a Canadian Cancer Society Research scientist.

PII: S1053-4296(10)00043-3

doi:10.1016/j.semradonc.2010.06.001

Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 274-281, October 2010

Article Tools

* Image Usage & Resolution